135 related articles for article (PubMed ID: 25459396)
1. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.
Millot F; Guilhot J; Baruchel A; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Nicolas Sirvent ; Yacouben K; Chastagner P; Gandemer V; Reguerre Y; Couillault G; Khalifeh T; Rialland F
Eur J Cancer; 2014 Dec; 50(18):3206-11. PubMed ID: 25459396
[TBL] [Abstract][Full Text] [Related]
2. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.
Shima H; Tokuyama M; Tanizawa A; Tono C; Hamamoto K; Muramatsu H; Watanabe A; Hotta N; Ito M; Kurosawa H; Kato K; Tsurusawa M; Horibe K; Shimada H
J Pediatr; 2011 Oct; 159(4):676-81. PubMed ID: 21592517
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
Rastogi MV; Stork L; Druker B; Blasdel C; Nguyen T; Boston BA
Pediatr Blood Cancer; 2012 Nov; 59(5):840-5. PubMed ID: 22378641
[TBL] [Abstract][Full Text] [Related]
4. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.
Narayanan KR; Bansal D; Walia R; Sachdeva N; Bhansali A; Varma N; Marwaha RK
Pediatr Blood Cancer; 2013 Jul; 60(7):1148-53. PubMed ID: 23322583
[TBL] [Abstract][Full Text] [Related]
5. Imatinib has adverse effect on growth in children with chronic myeloid leukemia.
Bansal D; Shava U; Varma N; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2012 Sep; 59(3):481-4. PubMed ID: 22052850
[TBL] [Abstract][Full Text] [Related]
6. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
[TBL] [Abstract][Full Text] [Related]
7. Effect of imatinib on growth in children with chronic myeloid leukemia.
Boddu D; Thankamony P; Guruprasad CS; Nair M; Rajeswari B; Seetharam S
Pediatr Hematol Oncol; 2019 May; 36(4):189-197. PubMed ID: 31298597
[TBL] [Abstract][Full Text] [Related]
8. Nonhematologic toxicity of imatinib mesylate in pediatric patients with chronic myelogenous leukemia: a predominance of musculoskeletal pain.
Heym KM; Gressett Ussery SM; Trinkman H; Philpot LM
J Pediatr Hematol Oncol; 2015 Mar; 37(2):e111-3. PubMed ID: 25374285
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate-induced pseudoporphyria in two children.
Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
[TBL] [Abstract][Full Text] [Related]
10. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
12. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
13. Imatinib induces body mass changes in women with chronic myeloid leukemia.
Breccia M; Salaroli A; Serrao A; Zacheo I; Alimena G
Ann Hematol; 2013 Nov; 92(11):1581-2. PubMed ID: 23580151
[No Abstract] [Full Text] [Related]
14. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate causes growth plate closure in vivo.
Vandyke K; Dewar AL; Fitter S; Menicanin D; To LB; Hughes TP; Zannettino AC
Leukemia; 2009 Nov; 23(11):2155-9. PubMed ID: 19626049
[No Abstract] [Full Text] [Related]
16. Long-term imatinib treatment does not cause testicular toxicity in male adolescents with chronic myeloid leukemia and in a juvenile rat model.
Tauer JT; Ulmer A; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2014 May; 226(3):169-74. PubMed ID: 24819387
[TBL] [Abstract][Full Text] [Related]
17. Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia.
Zheng FY; Lu AD; Zuo YX; Jia YP; Wu J; Zhang LP
Leuk Res; 2020 Aug; 95():106405. PubMed ID: 32590107
[TBL] [Abstract][Full Text] [Related]
18. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
19. Pattern of pediatric chronic myeloid leukemia in Sudan and hematological response to imatinib.
Alkhatib MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):100-5. PubMed ID: 21083363
[TBL] [Abstract][Full Text] [Related]
20. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.
Estabragh ZR; Knight K; Watmough SJ; Lane S; Vinjamuri S; Hart G; Clark RE
Leuk Res; 2011 Jan; 35(1):49-51. PubMed ID: 21030079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
